Abstract
Background: Polycystic ovary syndrome (PCOS) is a condition in which the ovaries produce an abnormal amount of androgens, male sex hormones that are usually present in women in small amounts. The name polycystic ovary syndrome describes the numerous small cysts (fluid-filled sacs) that form in the ovaries. Objective: This study aimed to evaluate the therapeutic role of Daflon versus myoinositol (MI) in improving the reproductive function in the rat model of PCOS. Methods: Oral letrozole(LTZ) combined with a high-fat diet for 21 days was used to induce the PCOS in Wister rats, group 1: 8 female Wister rats received only the vehicle C.M.C (carboxy methyl cellulose) for 21 days, group 2: received LTZ solution orally for 21days on daily bases(induction group) group 3: received LTZ for 21 days for PCOS induction than after that, Daflon 100mg/kg (DAF-H) for the next 21 days, group 4: recived LTA for 21 days for PCOS induction then received Daflon 50mg/kg (DAF-L) for the next 21 days, and group 5: recived LTZ for 21 days for PCOS induction then MI were administered for the following 21 days. Results: The LTZ-induced PCOS rats have lost their estrous cyclicity and become fixed at the diestrus phase, developed, abnormal sex and gonadotrophin hormone serum levels, increased cystic follicles, decreased number of the growing follicles, and very little or no corpora lutea on microscopic examination, which were reversed by the three drugs, DAF-H, DAF-L, and myoinositol.DAF-H and myoinositol were mostly equally effective in improving the reproductive manifestations of the disease. However, DAF-L was effective in returning the estrus cycle regulatory but yet not as effective in improving the condition compared to DAF-H and MI in this LTZ-induced model of PCOS. Conclusion: Daflon had the potential to ameliorate polycystic ovarian syndrome at the dose of 100mg/kg which is statistically comparable with myo-inositol. This property might be attributed to antioxidant activity of Daflon.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.